SARS-CoV-2 Infection and Transmission Inhibitor

Subhash Chandra1, 2, *
, Sakshi2, Sarla Saklani2, Alka N Choudhary1, Kanishk Kala3
1 Department of Pharmaceutical Chemistry, SGRR University, Patel Nagar-248001, Dehradun Uttarakhand, India
2 Department of Pharmaceutical Chemistry, Hemvati Nandan Bahuguna Garhwal (A Central) University, Srinagar Garhwal 246174, Uttarakhand, India
3 Department of Clinical Pharmacy, SGRR University, Patel Nagar 248001, Dehradun Uttarakhan, India

Article Metrics

CrossRef Citations:
Total Statistics:

Full-Text HTML Views: 176
Abstract HTML Views: 109
PDF Downloads: 103
ePub Downloads: 68
Total Views/Downloads: 456
Unique Statistics:

Full-Text HTML Views: 123
Abstract HTML Views: 81
PDF Downloads: 90
ePub Downloads: 57
Total Views/Downloads: 351

Creative Commons License
© 2023 Chandra et al.

open-access license: This is an open access article distributed under the terms of the Creative Commons Attribution 4.0 International Public License (CC-BY 4.0), a copy of which is available at: This license permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

* Address correspondence to this author at the Department of Pharmaceutical Chemistry, SGRR University and Hemvati Nandan Bahuguna Garhwal (A Central) University, Patel Nagar 248001, Srinagar Garhwal, Dehradun Uttarakhand, India; Tel: +91 9557010556; E-mail:


As of December 2019, there has been an outbreak of severe respiratory syndrome coronavirus-2 (SARS-CoV-2) in China. Around 16% of patients developed acute respiratory distress syndrome, and 1%–2% died. There is no specific treatment reported. A pandemic related to Coronavirus is one of the most significant health crises in human history. In spite of a massive influx of cases, SARS-CoV-2 is still untreatable. Both old and novel virologic medicines were tested in order to develop a novel drug or vaccine. In advanced clinical trials in the US, favipiravir is currently approved for treating influenza infections in Japan, and it has been approved for treating SARS-CoV-2 or COVID-19 infections in Japan. Studies have shown that favipiravir can treat mild to moderate COVID-19 infections. The present review examines the role and use of favipiravir in the treatment of COVID-19. The purpose of this review is to provide evidence obtained from a variety of authentic sources. Current research is evaluating favipiravir for treating Coronavirus infections.

Keywords: COVID-19, SARS-CoV-2, Favipiravir, Antiviral drugs, Nucleocapsids, Fecal-oral, Respiratory failure.